Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.

Kuppen MCP, Westgeest HM, van den Eertwegh AJM, van Moorselaar RJA, van Oort IM, Coenen JLLM, van den Bergh ACMF, Mehra N, Somford DM, Bergman AM, Ten Bokkel Huinink D, Fossion L, Geenen MM, Hendriks MP, van de Luijtgaarden ACM, Polee MB, Weijl NI, van de Wouw AJ, de Wit R, Uyl-de Groot CA, Gerritsen WR.

Eur Urol Oncol. 2019 Oct 7. pii: S2588-9311(19)30146-4. doi: 10.1016/j.euo.2019.09.005. [Epub ahead of print]

PMID:
31601523
2.

Systematic reviews as a "lens of evidence": Determinants of cost-effectiveness of breast cancer screening.

Mandrik O, Ekwunife OI, Meheus F, Severens JLH, Lhachimi S, Uyl-de Groot CA, Murillo R.

Cancer Med. 2019 Sep 30. doi: 10.1002/cam4.2498. [Epub ahead of print] Review.

3.

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.

Holleman MS, Al MJ, Zaim R, Groen HJM, Uyl-de Groot CA.

Eur J Health Econ. 2019 Sep 20. doi: 10.1007/s10198-019-01117-3. [Epub ahead of print]

PMID:
31541309
4.

Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.

Westgeest HM, Kuppen MCP, van den Eertwegh AJM, de Wit R, Coenen JLLM, van den Berg HPP, Mehra N, van Oort IM, Fossion LMCL, Hendriks MP, Bloemendal HJ, van de Luijtgaarden ACM, Ten Bokkel Huinink D, van den Bergh ACMF, van den Bosch J, Polee MB, Weijl N, Bergman AM, Uyl-de Groot CA, Gerritsen WR.

Clin Genitourin Cancer. 2019 Oct;17(5):e946-e956. doi: 10.1016/j.clgc.2019.05.018. Epub 2019 May 31.

PMID:
31439536
5.

[Loss is gain? Discarding TNF-α inhibitors].

Versteegh MM, Attema AE, Uyl-de Groot CA.

Ned Tijdschr Geneeskd. 2019 Mar 21;163. pii: D3709. Dutch.

PMID:
30945830
6.

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis.

Holleman MS, van Tinteren H, Groen HJ, Al MJ, Uyl-de Groot CA.

Onco Targets Ther. 2019 Feb 20;12:1413-1421. doi: 10.2147/OTT.S189438. eCollection 2019. Review.

7.

Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non-Small Cell Lung Cancer Using Real-World Data.

Holleman MS, Uyl-de Groot CA, Goodall S, van der Linden N.

Value Health. 2019 Mar;22(3):322-331. doi: 10.1016/j.jval.2018.08.007. Epub 2018 Oct 26.

PMID:
30832970
8.

Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma.

Leeneman B, Franken MG, Coupé VMH, Hendriks MP, Kruit W, Plaisier PW, van Ruth S, Verstijnen JAMC, Wouters MWJM, Blommestein HM, Uyl-de Groot CA.

Eur J Surg Oncol. 2019 May;45(5):825-831. doi: 10.1016/j.ejso.2019.01.225. Epub 2019 Feb 5.

PMID:
30765270
9.

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.

Blommestein HM, van Beurden-Tan CHY, Franken MG, Uyl-de Groot CA, Sonneveld P, Zweegman S.

Haematologica. 2019 May;104(5):1026-1035. doi: 10.3324/haematol.2018.206912. Epub 2019 Jan 3.

10.

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.

van Ommen-Nijhof A, Konings IR, van Zeijl CJJ, Uyl-de Groot CA, van der Noort V, Jager A, Sonke GS; SONIA study steering committee.

BMC Cancer. 2018 Nov 20;18(1):1146. doi: 10.1186/s12885-018-4978-1.

11.

Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran.

Ansaripour A, Zendehdel K, Tadayon N, Sadeghi F, Uyl-de Groot CA, Redekop WK.

PLoS One. 2018 Oct 1;13(10):e0205079. doi: 10.1371/journal.pone.0205079. eCollection 2018.

12.

A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia.

Kloos RQH, van Litsenburg RRL, Wolf S, Wismans L, Kaspers GJL, Uyl-de Groot CA, Pieters R, van der Sluis IM.

Pediatr Blood Cancer. 2019 Jan;66(1):e27458. doi: 10.1002/pbc.27458. Epub 2018 Sep 23.

PMID:
30246496
13.

Reply to 'Economic comments on proposal for a novel cancer drug pricing model'.

Uyl-de Groot CA, Löwenberg B.

Nat Rev Clin Oncol. 2018 Sep;15(9):588. doi: 10.1038/s41571-018-0084-1. No abstract available.

PMID:
30104695
14.

Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model.

Thielen FW, Blommestein HM, Oosten LEM, Calkoen FG, Lankester AC, Zwaginga JJ, Le Blanc K, Redondo A, Sánchez-Guijo F, Algeri M, Locatelli F, Fibbe WE, Uyl-de Groot CA.

Eur J Haematol. 2018 Aug 6. doi: 10.1111/ejh.13158. [Epub ahead of print]

PMID:
30084111
15.

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands.

Uyl-de Groot CA, van Rooijen EM, Punt CJA, Pescott CP.

Health Econ Rev. 2018 Jul 17;8(1):13. doi: 10.1186/s13561-018-0197-3. Review.

16.

Reply to 'Response to proposal for a novel cancer drug pricing model'.

Uyl-de Groot CA, Löwenberg B.

Nat Rev Clin Oncol. 2018 Aug;15(8):528-529. doi: 10.1038/s41571-018-0063-6. No abstract available.

PMID:
29955113
17.

Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.

Franken MG, Kanters TA, Coenen JL, de Jong P, Koene HR, Lugtenburg PJ, Jager A, Uyl-de Groot CA.

Anticancer Drugs. 2018 Sep;29(8):791-801. doi: 10.1097/CAD.0000000000000648.

PMID:
29846248
18.

Sustainability and affordability of cancer drugs: a novel pricing model.

Uyl-de Groot CA, Löwenberg B.

Nat Rev Clin Oncol. 2018 Jul;15(7):405-406. doi: 10.1038/s41571-018-0027-x. No abstract available.

PMID:
29735987
19.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, Groenewegen G, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, Uyl-de Groot CA, van der Hoeven KJM.

Anticancer Drugs. 2018 Jul;29(6):572-578. doi: 10.1097/CAD.0000000000000629.

PMID:
29659371
20.

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven KJM, Hospers GAP, Kapiteijn E, Koornstra R, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl M, Haanen JBAG, Uyl-de Groot CA.

Anticancer Drugs. 2018 Jul;29(6):579-588. doi: 10.1097/CAD.0000000000000628.

PMID:
29634490
21.

Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.

Ansaripour A, Uyl-de Groot CA, Redekop WK.

Pharmacoeconomics. 2018 Apr;36(4):505. doi: 10.1007/s40273-018-0634-5.

PMID:
29476362
22.

Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'.

Ansaripour A, Uyl-de Groot CA, Redekop WK.

Pharmacoeconomics. 2018 Mar;36(3):381-382. doi: 10.1007/s40273-018-0620-y. No abstract available.

PMID:
29427071
23.

Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe.

Gaultney JG, Ng TW, Uyl-de Groot CA, Sonneveld P, van Beers EH, van Vliet MH, Redekop WK.

Pharmacogenomics. 2018 Feb;19(3):213-226. doi: 10.2217/pgs-2017-0140. Epub 2018 Jan 15.

PMID:
29334316
24.

Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.

Oosten LEM, Chamuleau MED, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK, Smeekes OS, Kersten MJ, Hardi L, Baars JW, Demandt AMP, Stevens WBC, Nijland M, van Imhoff GW, Brouwer R, Uyl-de Groot CA, Kluin PM, de Jong D, Veelken H.

Ann Hematol. 2018 Feb;97(2):255-266. doi: 10.1007/s00277-017-3167-7. Epub 2017 Dec 6.

25.

MODEL-BASED COST-EFFECTIVENESS OF CONVENTIONAL AND INNOVATIVE CHEMO-RADIATION IN LUNG CANCER.

Bongers ML, de Ruysscher D, Oberije C, Lambin P, Uyl-de Groot CA, Belderbos J, Coupé VMH.

Int J Technol Assess Health Care. 2017 Jan;33(6):681-690. doi: 10.1017/S0266462317000939. Epub 2017 Nov 10.

PMID:
29122046
26.

Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma.

de Groot S, Redekop WK, Versteegh MM, Sleijfer S, Oosterwijk E, Kiemeney LALM, Uyl-de Groot CA.

Qual Life Res. 2018 Jan;27(1):115-124. doi: 10.1007/s11136-017-1704-4. Epub 2017 Sep 15.

27.

Developing a decision tool to identify patients with personality disorders in need of highly specialized care.

Goorden M, Willemsen EMC, Bouwmans-Frijters CAM, Busschbach JJV, Noomx MJ, van der Feltz-Cornelis CM, Uyl-de Groot CA, Hakkaart-van Roijen L.

BMC Psychiatry. 2017 Aug 31;17(1):317. doi: 10.1186/s12888-017-1460-6.

28.

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.

Gronde TV, Uyl-de Groot CA, Pieters T.

PLoS One. 2017 Aug 16;12(8):e0182613. doi: 10.1371/journal.pone.0182613. eCollection 2017. Review.

29.

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.

Ansaripour A, Uyl-de Groot CA, Redekop WK.

Pharmacoeconomics. 2018 Jan;36(1):91-103. doi: 10.1007/s40273-017-0557-6. Erratum in: Pharmacoeconomics. 2018 Feb 23;:.

30.

A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.

Kloos RQH, Uyl-de Groot CA, van Litsenburg RRL, Kaspers GJL, Pieters R, van der Sluis IM.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26651. Epub 2017 Aug 2.

PMID:
28766887
31.

Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.

Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, de Wit R, van den Bergh ACM, Coenen JLLM, Beerlage HP, Hendriks MP, Bos MMEM, van den Berg P, van de Wouw AJ, Spermon R, Boerma MO, Geenen MM, Tick LW, Polee MB, Bloemendal HJ, Cordia I, Peters FPJ, de Vos AI, van den Bosch J, van den Eertwegh AJM, Gerritsen WR.

Eur Urol Focus. 2018 Sep;4(5):694-701. doi: 10.1016/j.euf.2016.09.008. Epub 2016 Oct 13.

PMID:
28753794
32.

Reply to X. Armoiry et al.

van Beurden-Tan CHY, Franken MG, Blommestein HM, Uyl-de Groot CA, Blommestein HM, Uyl-de Groot CA, Sonneveld P.

J Clin Oncol. 2017 Sep 1;35(25):2976-2977. doi: 10.1200/JCO.2017.73.7569. Epub 2017 Jul 12. No abstract available.

PMID:
28700279
33.

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.

De Groot S, Blommestein HM, Redekop WK, Sleijfer S, Kiemeney LALM, Oosterwijk E, Uyl-de Groot CA.

PLoS One. 2017 May 22;12(5):e0177364. doi: 10.1371/journal.pone.0177364. eCollection 2017.

34.

Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences.

de Groot S, van der Linden N, Franken MG, Blommestein HM, Leeneman B, van Rooijen E, Koos van der Hoeven JJ, Wouters MW, Westgeest HM, Uyl-de Groot CA.

Value Health. 2017 Apr;20(4):627-636. doi: 10.1016/j.jval.2016.02.007. Epub 2016 Apr 6.

35.

Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.

van Beurden-Tan CHY, Franken MG, Blommestein HM, Uyl-de Groot CA, Sonneveld P.

J Clin Oncol. 2017 Apr 20;35(12):1312-1319. doi: 10.1200/JCO.2016.71.1663. Epub 2017 Feb 27. Review.

PMID:
28240968
36.

Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.

Franken MD, van Rooijen EM, May AM, Koffijberg H, van Tinteren H, Mol L, Ten Tije AJ, Creemers GJ, van der Velden AMT, Tanis BC, Uyl-de Groot CA, Punt CJA, Koopman M, van Oijen MGH.

Eur J Cancer. 2017 Apr;75:204-212. doi: 10.1016/j.ejca.2017.01.019. Epub 2017 Feb 24.

PMID:
28237866
37.

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.

Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC, Groenewegen G, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MW, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ.

Eur J Cancer. 2017 Feb;72:156-165. doi: 10.1016/j.ejca.2016.11.021. Epub 2016 Dec 25.

PMID:
28030784
38.

Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.

Blommestein HM, de Groot S, Aarts MJ, Vemer P, de Vries R, van Abeelen AF, Posthuma EF, Uyl-de Groot CA.

Leuk Res. 2016 Nov;50:37-45. doi: 10.1016/j.leukres.2016.09.005. Epub 2016 Sep 3.

39.
40.

Using Appropriate Methods in Cost-Effectiveness Analyses: The Case of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease.

Thielen FW, Blommestein HM, Uyl-de Groot CA.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2109-2110. doi: 10.1016/j.bbmt.2016.08.022. Epub 2016 Sep 13. No abstract available.

41.

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.

De Groot S, Sleijfer S, Redekop WK, Oosterwijk E, Haanen JB, Kiemeney LA, Uyl-de Groot CA.

BMC Cancer. 2016 Jun 11;16:364. doi: 10.1186/s12885-016-2395-x.

42.

Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.

de Groot S, Redekop WK, Sleijfer S, Oosterwijk E, Bex A, Kiemeney LA, Uyl-de Groot CA.

Urology. 2016 Sep;95:121-7. doi: 10.1016/j.urology.2016.04.042. Epub 2016 May 11.

PMID:
27179773
43.

THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS.

Buisman LR, Rutten-van Mölken MP, Postmus D, Luime JJ, Uyl-de Groot CA, Redekop WK.

Int J Technol Assess Health Care. 2016 Jan;32(1-2):46-53. doi: 10.1017/S0266462316000064. Epub 2016 Mar 22.

PMID:
27002226
44.

Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.

Maan R, Zaim R, van der Meer AJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Manns MP, Zeuzem S, Hansen BE, Janssen H, Veldt BJ, de Knegt RJ, Uyl-de Groot CA.

J Gastroenterol Hepatol. 2016 Nov;31(11):1851-1859. doi: 10.1111/jgh.13373.

PMID:
26990109
45.

Cost-utility of sentinel lymph node biopsy in cT1-T2N0 oral cancer.

van der Linden N, Flach GB, de Bree R, Uyl-de Groot CA.

Oral Oncol. 2016 Feb;53:20-6. doi: 10.1016/j.oraloncology.2015.11.011. Epub 2015 Nov 26.

PMID:
26631953
46.

Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the Netherlands.

van der Linden N, Bongers ML, Coupé VMH, Smit EF, Groen HJM, Welling A, Schramel FMNH, Uyl-de Groot CA.

Clin Lung Cancer. 2017 Sep;18(5):e341-e347. doi: 10.1016/j.cllc.2015.11.011. Epub 2015 Nov 30.

PMID:
28347579
47.

Costs of non-small cell lung cancer in the Netherlands.

van der Linden N, Bongers ML, Coupé VM, Smit EF, Groen HJ, Welling A, Schramel FM, Uyl-de Groot CA.

Lung Cancer. 2016 Jan;91:79-88. doi: 10.1016/j.lungcan.2015.10.015. Epub 2015 Oct 17.

PMID:
26589654
48.

Primary care in cancer control: towards mature cancer care.

Uyl-de Groot CA, Brouwer WB, de Maeseneer JM, Verweij J.

Lancet Oncol. 2015 Sep;16(12):1226-7. doi: 10.1016/S1470-2045(15)00294-6. No abstract available.

PMID:
26431862
49.

Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study.

Holtzer-Goor KM, Schaafsma MR, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Uyl-de Groot CA.

Qual Life Res. 2015 Dec;24(12):2895-906. doi: 10.1007/s11136-015-1039-y. Epub 2015 Jul 24.

50.

A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.

Blommestein HM, Verelst SG, de Groot S, Huijgens PC, Sonneveld P, Uyl-de Groot CA.

Eur J Haematol. 2016 Feb;96(2):198-208. doi: 10.1111/ejh.12571. Epub 2015 May 7.

PMID:
25892333

Supplemental Content

Loading ...
Support Center